copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting . . . Rigel's poster presentations will include data for GAVRETO ® (pralsetinib) for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), including final data from the Phase 1 2 ARROW study, and REZLIDHIA ® (olutasidenib) for the treatment of relapsed or refractory (R R) mutated
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib . . . "The resolution of this patent litigation underscores the strength of Rigel's intellectual property protecting TAVALISSE, an innovative treatment for people with immune thrombocytopenia," said Raul Rodriguez, Rigel's president and CEO
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS R289 1, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies
Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for . . . SOUTH SAN FRANCISCO, Calif , Oct 24, 2024 PRNewswire -- Rigel Pharmaceuticals, Inc ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO ® (pralsetinib) after
Rigels Fostamatinib Being Studied by National Institute of Health in . . . SOUTH SAN FRANCISCO, Calif , Jan 22, 2025 PRNewswire -- Rigel Pharmaceuticals, Inc (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral spleen tyrosine kinase (SYK) inhibitor, in patients with sickle cell disease